UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis

Annals of oncology, 2018-04, Vol.29 (4), p.895-902

2018

Volltextzugriff (PDF)

Linear mixed-effects models for central statistical monitoring of multicenter clinical trials

Statistics in medicine, 2014-12, Vol.33 (30), p.5265-5279

2014

Volltextzugriff (PDF)

First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)

Annals of oncology, 2019-05, Vol.30, p.iii48-iii48

2019

Volltextzugriff (PDF)

Dissecting the Akt/mTOR pathway in estrogen receptor positive breast cancers identifies phosphorylated Akt signature to be associated with luminal A and good prognosis in contrast to phosphorylated mTOR

Breast (Edinburgh), 2017-03, Vol.32, p.S103-S103

2017

Volltextzugriff (PDF)

The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab

ESMO open, 2024-05, Vol.9 (5), p.102964-102964, Article 102964

2024

Volltextzugriff (PDF)

Identification of new phases in annealed Fe–18CrWTi ODS powders

Journal of nuclear materials, 2010-04, Vol.399 (2), p.219-224

2010

Volltextzugriff (PDF)

Absence of a specific radiation signature in post-Chernobyl thyroid cancers

British journal of cancer, 2005-04, Vol.92 (8), p.1545-1552

2005

Volltextzugriff (PDF)

Separation of samples into their constituents using gene expression data

Bioinformatics, 2001-06, Vol.17 (suppl-1), p.S279-S287

2001

Volltextzugriff (PDF)

1811 Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial

European journal of cancer (1990), 2015-09, Vol.51, p.S269-S269

2015

Volltextzugriff (PDF)

Abstract P2-07-02: Uncovering TNBC molecular heterogeneity by applying integrative “omics” analyses with potential clinical implications

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-07-02

2018

Volltextzugriff (PDF)

Integrating spatial and single cell transcriptomics to identify and characterize biologically driven subgroups in invasive lobular carcinoma

European journal of cancer (1990), 2024-03, Vol.200, p.113620, Article 113620

2024

Volltextzugriff (PDF)

Unravelling tumor heterogeneity in patients with HER2-low hormone receptor-positive breast cancer using spatial transcriptomics

European journal of cancer (1990), 2024-03, Vol.200, p.113834, Article 113834

2024

Volltextzugriff (PDF)

1711P Spatial transcriptomics reveals substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications

Annals of oncology, 2022-09, Vol.33, p.S1321-S1322

2022

Volltextzugriff (PDF)

136MO Differential benefit of low-dose cyclophosphamide and methotrexate maintenance chemotherapy among TNBC subtypes in the context of the IBCSG 22-00 study

Annals of oncology, 2022-09, Vol.33, p.S601

2022

Volltextzugriff (PDF)

1726P Investigating adipocytes-tumor cells interaction and its effect on disease progression in lobular breast cancer with spatial transcriptomics

Annals of oncology, 2022-09, Vol.33, p.S1326

2022

Volltextzugriff (PDF)

257P Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort

Annals of oncology, 2024-09, Vol.35, p.S322-S322

2024

Volltextzugriff (PDF)

139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial

Annals of oncology, 2022-09, Vol.33, p.S602-S603

2022

Volltextzugriff (PDF)

341MO Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA program (BIG 14-01) subanalysis

Annals of oncology, 2024-09, Vol.35, p.S357-S358

2024

Volltextzugriff (PDF)

43P Deciphering spatial expression of trop-2, HER2, and AR: Towards customized treatments in triple-negative breast cancer

ESMO open, 2024-05, Vol.9, p.103050, Article 103050

2024

Volltextzugriff (PDF)

Abstract P3-06-02: Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-06-02

2019

Volltextzugriff (PDF)

2MO Development of a prognostic gene-expression signature for early stage HER2-positive breast cancer patients

Annals of oncology, 2022-05, Vol.33, p.S124-S124

2022

Volltextzugriff (PDF)

A statistical approach to central monitoring of data quality in clinical trials

Clinical trials (London, England), 2012-12, Vol.9 (6), p.705-713

2012

Volltextzugriff (PDF)

P242 - Dissecting the Akt/mTOR pathway in estrogen receptor positive breast cancers identifies phosphorylated Akt signature to be associated with luminal A and good prognosis in contrast to phosphorylated mTOR

Breast (Edinburgh), 2017-03, Vol.32, p.S103-S103

2017

Volltextzugriff (PDF)

Abstract P4-06-03: Unravelling triple-negative breast cancer tumor microenvironment heterogeneity using an integrative multiomic analysis

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-06-03

2019

Volltextzugriff (PDF)

1 – 25 von 475

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(303)
Mit Volltextzugriff
(337)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis

Linear mixed-effects models for central statistical monitoring of multicenter clinical trials

First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)

Dissecting the Akt/mTOR pathway in estrogen receptor positive breast cancers identifies phosphorylated Akt signature to be associated with luminal A and good prognosis in contrast to phosphorylated mTOR

The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab

Identification of new phases in annealed Fe–18CrWTi ODS powders

Absence of a specific radiation signature in post-Chernobyl thyroid cancers

Separation of samples into their constituents using gene expression data

1811 Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial

Abstract P2-07-02: Uncovering TNBC molecular heterogeneity by applying integrative “omics” analyses with potential clinical implications

Integrating spatial and single cell transcriptomics to identify and characterize biologically driven subgroups in invasive lobular carcinoma

Unravelling tumor heterogeneity in patients with HER2-low hormone receptor-positive breast cancer using spatial transcriptomics

1711P Spatial transcriptomics reveals substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications

136MO Differential benefit of low-dose cyclophosphamide and methotrexate maintenance chemotherapy among TNBC subtypes in the context of the IBCSG 22-00 study

Le Mal et ses masques

1726P Investigating adipocytes-tumor cells interaction and its effect on disease progression in lobular breast cancer with spatial transcriptomics

257P Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort

139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial

341MO Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA program (BIG 14-01) subanalysis

43P Deciphering spatial expression of trop-2, HER2, and AR: Towards customized treatments in triple-negative breast cancer

Abstract P3-06-02: Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer

2MO Development of a prognostic gene-expression signature for early stage HER2-positive breast cancer patients

A statistical approach to central monitoring of data quality in clinical trials

P242 - Dissecting the Akt/mTOR pathway in estrogen receptor positive breast cancers identifies phosphorylated Akt signature to be associated with luminal A and good prognosis in contrast to phosphorylated mTOR

Abstract P4-06-03: Unravelling triple-negative breast cancer tumor microenvironment heterogeneity using an integrative multiomic analysis

Suchergebnisse filtern